Amneal Pharmaceuticals LLC is a fast-growing US generics manufacturer dedicated to providing outstanding quality prescription and OTC medications and exceptional service to pharmacists and their patients. The Amneal culture is driven by high integrity, superior execution across all operations, a strong sense of family values, and commitment to forging deep relationships with customers and business partners that create value. More than 144 million prescriptions are filled annually with the company’s products, according to April 2014 IMS Health data, and 8 of its top 10 products are #1 in their respective markets.
Generic drug quality is making headlines these days, and Amneal is relentlessly focused on ensuring the quality of its products from initial development through commercial production. As Amneal makes all its products, it is ever mindful that they are to be consumed by humans. “There isn’t a single item we produce that we wouldn’t use on our own loved ones,” explains Amneal co-CEO & co-chairman Chirag Patel. The firm strives to manufacture superior-quality pharmaceuticals as efficiently as possible. All 9 Amneal state-of-the-art production facilities, both US and international, are certified to the same exacting FDA standards. Seven US plants produce 95% of the company’s products, while the international sites are primarily focused on ex-US markets.
Extensive Product Selection
Amneal’s diversified portfolio now counts 76 FDA-approved generics in a wide range of therapeutic areas. In its robust pipeline, 90 ANDAs are currently on file and more than 140 products are under development. Amneal medications are used to treat the central nervous system; pain; cardiovascular, urologic, and dermatologic conditions; cancer; opioid dependency; women’s health issues; and diabetes, among other indications.
Current dosage forms include tablets, capsules, softgels, and oral liquids. Products filed with the FDA and in development include differentiated generics such as injectables, topicals, transdermals, transmucosals, creams, ointments, inhalers, nasal sprays, ophthalmics, and otics. Almost 100 new products representing $62 billion in market value are planned for launch within the next 3 years.
Earlier this year, Amneal introduced esomeprazole strontium and the first and only generic for Loestrin® 24 Fe, Lomedia™ 24 Fe. Other new offerings include Atovaquone Oral Solution and Zenchent® Fe, the generic for Femcon® Fe. Of more than 100 products in development, 22% are e-FTF, FTF, and FTM launches, while 33% are Paragraph IV generics. Amneal is aggressively expanding into high-value specialty generics, while continuing to supply high-volume commodity drugs. This balanced mix of high-volume and high-value products, together with nonprice value, delivers significant benefit to pharmacy customers.
Comprehensive Online Catalog
Extensive information on all Amneal products can be found in the online Product Catalog at amneal.com. This comprehensive resource is designed for easy access to in-depth product information such as product specifications, inactive ingredients, and allergens. Also posted on the product detail page are highresolution images, labels, full prescribing information, patient medication guides, material safety data sheets, and Healthcare Distribution Management Association sheets. With a few clicks, pharmacists and patients can locate the exact resources and answers they need.
A Passion for Excellence
Whether expanding into new markets or efficiently serving its loyal customers, Amneal has built a reputation for consistently providing superb quality generics, outstanding service levels, reliability of supply, and fast response to inquiries or problems.
As Amneal comes ever closer to its goal of becoming a top-5 US generics supplier, the company remains firmly committed to (1) the passionate pursuit of excellence throughout its operations, (2) dedication to its employees, and (3) the creation of superior customer value. These guiding principles are at the heart of Amneal’s approach to business and the reason for its tremendous success.
For more information, visit www.amneal.com.